INTRAOSSEOUS ADMINISTRATION OF CHEMOTHERAPY -- OSTEOPORT

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 19068
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1992
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
Lifequest Medical Inc
9601 Mcallister Freeway, San Antonio, TX, 78216
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Daniel T Castro
 (210) 366-2100
Business Contact
Phone: () -
Research Institution
N/A
Abstract
DIFFICULTY IN OBTAINING AND MAINTAINING INTRAVENOUS (I.V.) ACCESS FOR MEDICATION ADMINISTRATION IS A FREQUENT COMPLICATION ENCOUNTERED IN PATIENTS UNDERGOING CANCER CHEMOTHERAPY. IN THESE PATIENTS, POOR VENOUS ACCESS OR COMPLICATIONS RELATED TO INDWELLING VENOUS CATHETERS CAN LIMIT THE ADMINISTRATION OF LIFE-SAVING MEDICATIONS. THE OSTEOPORT IS A DEVICE DESIGNED FOR IMPLANTATION INTO THE BONE MARROW, FOR THE PURPOSE OF ADMINISTERING MEDICATIONS THAT TYPICALLY MUST BE GIVEN INTRAVENOUSLY. THIS RESEARCH WILL EVALUATE I.O. ADMINISTRATION OF THE ANTINEOPLASTIC AGENT DOXORUBICIN (DOX) THROUGH THE OSTEOPORT, IN AN ANIMAL (GOAT) MODEL. THE PHARMACOKINETICS OF DOX WILL BE COMPARED BETWEEN I.V. AND I.O. ADMINISTRATION BY MEASURING SERIAL PLASMA LEVELS OF DOX AFTER SINGLE I.V. AND I.O. DOSES, AND AFTER REPEATED I.O. DOSING. SIMILAR BIOAVAILABILITY OF DOX BY BOTH ROUTES OF ADMINISTRATION WILL HELP DEMONSTRATE THE SUITABILITY OF THE OSTEOPORT FOR ADMINISTRATION OF CANCER CHEMOTHERAPY. AT THE CONCLUSION OF THE STUDY, TISSUE SAMPLES WILL BE OBTAINED FROM THE OSTEOPORT IMPLANT SITE FOR HISTOLOGIC EVALUATION, TO DETERMINE IF LOCAL PATHOLOGY IS ASSOCIATED WITH REPEATED I.O. ADMINISTRATION OF DOX.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government